Skip to main content
Premium Trial:

Request an Annual Quote

Publicly Traded RNAi Drug Firms


With Rosetta Genomics prepping for an initial public offering during this year or next, it is set to join a handful of other companies in the RNAi drugs game that are traded on public markets. To date Alnylam Pharmaceuticals is the only firm to have floated its shares as an RNAi company; all the others were already public when they reorganized to focus on the gene-silencing technology.

Below is a breakdown of the public companies in the space.

Publicly Traded RNAi Drug Firms
Ticker Symbol
Date Founded
Date of IPO/Date Began Trading as RNAi Firm
Stock Price at IPO/Stock Price after Becoming RNAi Firm
Current Stock Price (as of Jan. 26)
Alnylam Pharmaceuticals ALNY July 2002 May 2004
Benitec BLT.AX February 1997 as Queensland Opal, an opal mining concern. Reorganized into RNAi firm in July 2002. Shares began trading on Australian Stock Exchange under Benitec name in July 2002.
CytRx CYTR February 1985. Began researching RNAi in April 2003 after corporate reorganization. Began trading as RNAi company in April 2003.
Genesis Research and Development GEN.AX September 2000. Shifted focus onto RNAi therapeutics around December 2003. Began trading on Australian Stock Exchange with new RNAi focus around December 2003.
Sirna Therapeutics RNAI January 1992. Changed name to Sirna Therapeutics from Ribozyme Pharmaceuticals, and shifted focus onto RNAi in April 2003. Began trading as Sirna Therapeutics in April 2003.
SR Pharma SPA.L November 1994. Began researching RNAi therapeutics after July 2005 acquisition of Atugen. Began trading on the London Stock Exchange with an RNAi focus in July 2005.
The Scan

Missed Early Cases

A retrospective analysis of blood samples suggests early SARS-CoV-2 infections may have been missed in the US, the New York Times reports.

Limited Journal Editor Diversity

A survey finds low diversity among scientific and medical journal editors, according to The Scientist.

How Much of a Threat?

Science writes that need for a provision aimed at shoring up genomic data security within a new US bill is being questioned.

PNAS Papers on Historic Helicobacter Spread, Brain Development, C. difficile RNAs

In PNAS this week: Helicobacter genetic diversity gives insight into human migrations, gene expression patterns of brain development, and more.